Human Risk and Organisational Resilience Advisory

See the human risk before it becomes a business problem.

Amstara helps life-science, medical technology, pharma, biotech and health-innovation organisations reduce the human, collaboration and decision risks that weaken trust, adoption and partnership value.

Start a Conversation

Strong innovation can still lose momentum

Health innovation often becomes vulnerable before a major failure is visible.

Early warning signs may include:

unclear customer value
misaligned partner expectations
weak decision ownership
limited trust
poor information flow
low confidence in adoption
concerns that are not raised early

These risks are often overlooked until resources are committed or contracts are signed.

Amstara helps organisations recognise them earlier.

The Business Risk

What Amstara Does

The human side of risk

Human risk is not about blaming people.

It arises when people lack the clarity, alignment, capability, trust or authority needed to make sound decisions and execute effectively.

Amstara assesses the organisational conditions that influence:

value understanding
stakeholder alignment
decision quality
customer confidence
learning and adoption
human oversight
effective execution

Our Service

A focused assessment that identifies the human, collaboration and execution risks that may weaken trust, adoption, partnerships and business value.

Value & Customer Relevance

Assess whether the innovation is clearly positioned and translated into practical value that customers, partners and stakeholders can understand, trust and act on.

Partnership & Stakeholder Alignment

Identify gaps in expectations, responsibilities, communication and trust before opportunities move into formal agreements or major commitments.

Decision Quality and Execution

Assess whether decision ownership, accountability, documentation and follow through are strong enough to support reliable execution within quality, standards and regulatory expectations.

Education, Training and Adoption

Identify gaps in education, learning pathways, expert support and training that may reduce customer confidence, practical use and long term adoption.

How We Work Together (Advisory Process)

From early signals to practical action

Discover
Review the initiative, operating context, key stakeholders and intended outcomes.

Diagnose
Identify patterns, gaps, assumptions and interconnected risks.

Prioritise
Determine which issues pose the greatest risk to trust, adoption and execution.

Strengthen
Translate the findings into focused actions and clear leadership recommendations.

Stronger human systems support stronger execution

Amstara helps organisations strengthen:

early risk recognition
customer and partner confidence
stakeholder alignment
decision ownership
adoption readiness
human oversight
execution discipline
organisational resilience

The goal is not to remove uncertainty.

It is to help organisations respond before uncertainty becomes damage.

Business Outcomes

Why Amstara

Science, business and human performance in one advisory lens

Health innovation sits at the intersection of evidence, regulation, technology, commercial value and human decision making.

Traditional reviews often assess products, processes, technical requirements, financial considerations and legal compliance separately.

Amstara focuses on the collaboration layer where these elements come together:

How people understand value, build trust, make decisions, learn, challenge assumptions and execute.

This is where many early risks become visible, and where timely action can protect business value.

Amstara supports health innovation organisations when they need to:

Clarify value

Translate complex science, technology or product value into clear customer and partner relevance.

Align stakeholders

Prepare for strategic partnerships and align scientific, commercial, quality, regulatory and operational teams before formal commitments are made.

Strengthen decisions and execution

Clarify ownership, decision flow, accountability and follow through across complex collaboration settings.

Improve education and adoption

Strengthen customer education, training and adoption pathways where limited understanding or confidence may slow practical use.

The earlier these issues are identified, the easier they are to address before they affect trust, resources or business value.

Typical Use Cases

About Amstara

Wen Koster, PhD

Founder and Advisor

Amstara is a founder led specialist advisory focused on human risk and organisational resilience in health innovation.

Founded by Wen Koster, PhD, Amstara brings more than 16 years of experience across biomedical science, translational research, regulated health innovation, product development and commercialisation, strategic business development, GMP related training, ISO standardisation coordination and international partnerships.

This experience spans scientific, commercial, regulatory, quality, intellectual property, operational and stakeholder environments. It includes coordination with NEN and contribution to a multinational global health partnership supported by the Bill & Melinda Gates Foundation.

Amstara combines this cross functional experience with a structured human performance perspective shaped by the Hintsa methodology. This supports a practical focus on stakeholder alignment, decision quality, learning effectiveness, communication discipline, resilience and execution under pressure.

Amstara supports life science, medical technology, pharmaceutical, biotechnology and health innovation organisations in identifying the human and collaboration risks that can weaken customer adoption, strategic partnerships and innovation value.

Preparing for a strategic collaboration, customer education programme or adoption challenge? Amstara can help identify where risk may arise before it affects trust, decisions, execution or value.